Cover Image
市場調查報告書

主要已發展市場的乳癌治療:支援HER2標靶藥物的持續支配的新治療方法認證

Breast Cancer Therapeutics in Major Developed Markets to 2020 - Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs

出版商 GBI Research 商品編碼 305016
出版日期 內容資訊 英文
訂單完成後即時交付
價格
Back to Top
主要已發展市場的乳癌治療:支援HER2標靶藥物的持續支配的新治療方法認證 Breast Cancer Therapeutics in Major Developed Markets to 2020 - Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs
出版日期: 2014年06月01日 內容資訊: 英文
簡介

乳癌治療的主要8國市場(美國、英國、法國、德國、西班牙、義大利、日本及加拿大)的市值,2013年為92億美金,今後將以年複合成長率5.1%成長,預計至2020年達到92億美元。在2013年中美國佔最大的市場佔有率,市值為55億美元(全球佔有率59%),第2名是日本(8億7150萬美元,9.4%),第3名是義大利(6億6850萬美元,7.2%)。

本報告提供全球主要已發展市場的乳癌治療市場相關調查、疾病概要、治療流程、治療的利用模式、乳癌市場市場規模與預測、乳癌的主要上市藥與產品實際成果的熱圖、全球乳癌開發平台的詳細分析、市場影響因素的預測,及策略分析等彙整。

第1章 目錄

第2章 主要已發展市場的乳癌治療:簡介

  • 乳癌
  • 症狀
  • 流行病學
  • 病理學
  • 診斷
  • 預後、分期
  • 治療選項

第3章 主要已發展市場的乳癌治療:上市藥

  • 主要的上市藥
  • 上市藥的熱圖

第4章 主要已發展市場的乳癌治療:開發平台分析

  • 整體開發平台
  • 開發平台分析:各分子類型
  • 開發平台分析:各作用機制
  • 臨床實驗:失敗率
  • 臨床實驗的規模
  • 繼續期間
  • 開發平台的有潛力候補藥

第5章 主要已發展市場的乳癌治療:市場預測

  • 全球市場
  • 北美
  • 市場歐洲的主要5個國家
  • 日本
  • 亞太地區市場上乳癌治療的促進要素、阻礙要素

第6章 主要已發展市場的乳癌治療:契約、策略性整合

  • 授權協定
  • 共同開發協定

第7章 附錄

圖表清單

目錄
Product Code: GBIHC332MR

GBI Research, the leading business intelligence provider, has released its latest research, "Breast Cancer Therapeutics in Major Developed Markets to 2020 - Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs", which provides in-depth analysis of breast cancer therapeutics market within the eight major geographies of the US, Canada, the top five geographies in Europe (the UK, France, Germany, Spain and Italy) and Japan. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

The breast cancer therapeutics market in the eight major markets - The US, The UK, France, Germany, Spain, Italy, Japan and Canada - was worth $9.2 billion in 2013, and is expected to grow at a Compound Annual Growth Rate (CAGR) of 5.1% to $13.1 billion by 2020. The US had the largest market in 2013, valued at $5.5 billion, equivalent to a global share of 59%, followed by Japan with $871.5m or 9.4% and Italy with $668.5m or 7.2%. Canada had the lowest market share and value of the leading eight at 2.9% and $268.4m, but is expected to witness rapid growth over the forecast period with a CAGR of 6.7%. This will only be surpassed by Japan, which is expected to witness growth at a CAGR of 6.9%.

Breast Cancer Therapeutics Market to Witness Moderate Growth

The breast cancer therapeutics market in the eight major markets - The US, The UK, France, Germany, Spain, Italy, Japan and Canada - was worth $9.2 billion in 2013, and is expected to grow at a Compound Annual Growth Rate (CAGR) of 5.1% to $13.1 billion by 2020. The US had the largest market in 2013, valued at $5.5 billion, equivalent to a global share of 59%, followed by Japan with $871.5m or 9.4% and Italy with $668.5m or 7.2%. Canada had the lowest market share and value of the leading eight at 2.9% and $268.4m, but is expected to witness rapid growth over the forecast period with a CAGR of 6.7%. This will only be surpassed by Japan, which is expected to witness growth at a CAGR of 6.9%.

The use of targeted therapies is expected to increase in the eight major markets, aided by the entry of a biosimilar of trastuzumab. Drugs in late stages of clinical trials such as palbociclib and neratinib from Pfizer, and afatinib from Boehringer Ingelheim, are expected to contribute towards the breast cancer market growth. The market is also expected to grow due to the increased uptake of Afinitor (everolimus), a novel targeted therapy from Novartis, despite the high cost of therapy. It will also be driven by Human Epidermal growth factor Receptor (HER)-2-targeting agents, antibody drug conjugate Kadcyla (ado-trastuzumab emtansine) and Eisai's Halaven (eribulin mesylate), a novel chemotherapeutic agent. The total value of the breast cancer market will increase slightly over the forecast period due to the increased uptake of branded drugs. This increase will occur despite the launch of trastuzumab biosimilars, which are likely to actively compete with branded Herceptin in the breast cancer therapeutics market. Market growth will be the result of the launch of a number of premium-priced agents, plus a gradual increase in the use of targeted therapies and a rise in the incidence population in the eight major markets.

Strong Pipeline to Drive Growth to 2020

The breast cancer pipeline is highly robust with potential drug candidates across various phases of clinical development. With over 600 active pipeline molecules, the majority of the investigational drug candidates are being evaluated for the treatment of breast cancer in advanced stages, either as first-line or second-line therapies.

The current investigational pipeline candidates include the new combination therapies, targeted therapies and promising immunotherapies, as well as chemotherapy drug candidates. In addition to these active progressing pipeline molecules, the pipeline also includes 390 molecules that are either inactive or discontinued.

As displayed in the following figure, from a total of 612 active progressing pipeline molecules, 259 (42%) are in the preclinical stage of development, 100 (16%) are in Phase I, 130 (21%) are in Phase II and 52 (8%) are in Phase III. A substantial number of active drug candidates are also in the discovery stage. As shown in panel B, most of the pipeline drugs are novel, and a few are either generic or products that have already been marketed for other indications.

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in the breast cancer in the major developed markets. The report includes -

  • Disease overview, as well as treatment algorithms and treatment usage patterns
  • Market size and forecast for the breast cancer market from 2012 to 2019
  • Major marketed products for breast cancer along with a heat map of product performance
  • In-depth pipeline analysis for global pipeline in breast cancer along with clinical trial failure rate analysis
  • Key drivers and restraints that have had and are expected to have a significant impact upon the market
  • Key licensing and co-development agreements that could have impact on growth trends

Reasons to buy

  • The report will enhance your decision-making capability by allowing you to -
  • Align your product portfolio to the markets with high growth potential
  • Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
  • Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the breast cancer therapeutics market
  • Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Breast Cancer Therapeutics in Major Developed Markets to 2020-Introduction

  • 2.1. Breast Cancer
  • 2.2. Symptoms
  • 2.3. Epidemiology
  • 2.4. Pathophysiology
  • 2.5. Diagnosis
  • 2.6. Prognosis and Disease Staging
    • 2.6.1. Classification
  • 2.7. Treatment Options
    • 2.7.1. Surgery and Radiation Therapy
    • 2.7.2. Chemotherapy
    • 2.7.3. Hormonal Therapies
    • 2.7.4. Targeted Therapies
    • 2.7.5. Resistance to Pharmacological Therapies
    • 2.7.6. Treatment Guidelines
    • 2.7.7. Measuring the Effectiveness of Treatment

3. Breast Cancer Therapeutics in Major Developed Markets to 2020-Marketed Products

  • 3.1. Key Marketed Products
    • 3.1.1. Herceptin
    • 3.1.2. Halaven
    • 3.1.3. Avastin
    • 3.1.4. Gemzar
    • 3.1.5. Taxotere
    • 3.1.6. Tykerb
    • 3.1.7. Femara
    • 3.1.8. Aromasin
    • 3.1.9. Zoladex
    • 3.1.10. Arimidex
  • 3.2. Heat Map for Marketed Products

4. Breast Cancer Therapeutics in Major Developed Markets to 2020-Pipeline Analysis

  • 4.1. Overall Pipeline
  • 4.2. Pipeline Analysis by Molecule Type
  • 4.3. Pipeline Analysis by Mechanism of Action
  • 4.4. Clinical Trials-Failure Rate
  • 4.5. Clinical Trial Size
  • 4.6. Duration
  • 4.7. Promising Drug Candidates in Pipeline
    • 4.7.1. Buparlisib
    • 4.7.2. Palbociclib
    • 4.7.3. Afatinib dimaleate
    • 4.7.4. Entinostat
    • 4.7.5. Neratinib
    • 4.7.6. BMN-673
    • 4.7.7. Etirinotecan pegol
    • 4.7.8. MetmAb (onartuzumab)

5. Breast Cancer Therapeutics in Major Developed Markets to 2020-Market Forecast to 2020

  • 5.1. Global Market
    • 5.1.1. Treatment Use Patterns
    • 5.1.2. Market Size
  • 5.2. North America
    • 5.2.1. Treatment Use Patterns
    • 5.2.2. Annual Cost of Therapy
    • 5.2.3. Market Size
  • 5.3. Top Five European Markets
    • 5.3.1. Treatment Use Patterns
    • 5.3.2. Annual Cost of Therapy
    • 5.3.3. Market Size
  • 5.4. Japan
    • 5.4.1. Treatment Use Patterns
    • 5.4.2. Annual Cost of Therapy
    • 5.4.3. Market Size
  • 5.5. Drivers and Barriers for the Breast Cancer Therapeutics in Asia-Pacific Market to 2020
    • 5.5.1. Drivers
    • 5.5.2. Barriers

6. Breast Cancer Therapeutics in Major Developed Markets to 2020-Deals and Strategic Consolidations

  • 6.1. Licensing Agreements
    • 6.1.1. Major Licensing Deals
  • 6.2. Co-development Agreements
    • 6.2.1. Major Co-development Agreements

7. Breast Cancer Therapeutics in Major Developed Markets to 2020-Appendix

  • 7.1. All Pipeline Drugs by Phase
    • 7.1.1. Discovery
    • 7.1.2. Preclinical
    • 7.1.3. IND/CTA-Filed and Phase I
    • 7.1.4. Phase II
    • 7.1.5. Phase III
    • 7.1.6. Pre-Registration
  • 7.2. Market Forecasts to 2020
    • 7.2.1. Global
    • 7.2.2. US
    • 7.2.3. Canada
    • 7.2.4. UK
    • 7.2.5. France
    • 7.2.6. Germany
    • 7.2.7. Italy
    • 7.2.8. Spain
    • 7.2.9. Japan
  • 7.3. Market Definitions
  • 7.4. Abbreviations
  • 7.5. References
  • 7.6. Research Methodology
    • 7.6.1. Coverage
    • 7.6.2. Secondary Research
    • 7.6.3. Primary Research
    • 7.6.4. Therapeutic Landscape
    • 7.6.5. Geographical Landscape
    • 7.6.6. Pipeline Analysis
  • 7.7. Expert Panel Validation
  • 7.8. Contact Us
  • 7.9. Disclaimer

List of Tables

  • Table 1: Breast Cancer Therapeutics, Global, Tumor, Nodes and Metastasis Staging, 2010-2013
  • Table 2: Breast Cancer Therapeutics, US, Disease Stage at Diagnosis and Five-Year Relative Survival (%), 2013
  • Table 3: Breast Cancer Therapeutics, Global, All Pipeline Products (Discovery), 2013
  • Table 4: Breast Cancer Therapeutics, Global, All Pipeline Products (Preclinical), 2013
  • Table 5: Breast Cancer Therapeutics, Global, All Pipeline Products (IND/CTA-Filed and Phase I), 2013
  • Table 6: Breast Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2013
  • Table 7: Breast Cancer Therapeutics, Global, All Pipeline Products (Phase III), 2013
  • Table 8: Breast Cancer Therapeutics, Global, All Pipeline Products (Pre-Registration), 2013
  • Table 9: Breast Cancer Therapeutics, Global, Forecast Data, 2013-2020
  • Table 10: Breast Cancer Therapeutics, US, Forecast Data, 2013-2020
  • Table 11: Breast Cancer Therapeutics, Canada, Forecast Data, 2013-2020
  • Table 12: Breast Cancer Therapeutics, UK, Forecast Data, 2013-2020
  • Table 13: Breast Cancer Therapeutics, France, Forecast Data, 2013-2020
  • Table 14: Breast Cancer Therapeutics, Germany, Forecast Data, 2013-2020
  • Table 15: Breast Cancer Therapeutics, Italy, Forecast Data, 2013-2020
  • Table 16: Breast Cancer Therapeutics, Spain, Forecast Data, 2013-2020
  • Table 17: Breast Cancer Therapeutics, Japan, Forecast Data, 2013-2020

List of Figures

  • Figure 1: Breast Cancer Therapeutics, Global, Treatment Algorithm for Cancer Diagnosed at Stages I to III, 2013
  • Figure 2: Breast Cancer Therapeutics, Global, Treatment Algorithm for Cancer Diagnosed at Stage IV, 2013
  • Figure 3: Breast Cancer Therapeutics, Global, Heat Map (Marketed Products)
  • Figure 4: Breast Cancer Therapeutics, Global, Pipeline by Stage of Development and Program Type, 2013
  • Figure 5: Breast Cancer Therapeutics, Global, Pipeline by Molecule Type and Stage of Development, 2013
  • Figure 6: Breast Cancer Therapeutics, Global, Pipeline by Mechanism of Action and Stage of Development, 2013
  • Figure 7: Breast Cancer Therapeutics, Global, Clinical Trial Failure Rate (%), 2013
  • Figure 8: Breast Cancer Therapeutics, Global, Clinical Trial Size, 2013
  • Figure 9: Breast Cancer Therapeutics, Global, Clinical Trial Duration (months), 2013
  • Figure 10: Breast Cancer Therapeutics, Global, Treatment Use Patterns ('000) and Market Size ($bn), 2013-2020
  • Figure 11: Breast Cancer Therapeutics, US and Canada, Treatment Use Patterns ('000), 2013-2020
  • Figure 12: Breast Cancer Therapeutics, US and Canada, Annual Cost of Therapy ($), 2013-2020
  • Figure 13: Breast Cancer Therapeutics, US and Canada, Market Size ($m), 2013-2020
  • Figure 14: Breast Cancer Therapeutics, Top Five European Markets, Treatment Use Patterns ('000), 2013-2020
  • Figure 15: Breast Cancer Therapeutics, Top Five European Markets, Annual Cost of Therapy ($), 2013-2020
  • Figure 16: Breast Cancer Therapeutics, Top Five European Markets, Market Size ($m), 2013-2020
  • Figure 17: Breast Cancer Therapeutics, Japan, Treatment Use Pattern, Annual Cost of Therapy and Market Size, 2013-2020
  • Figure 18: Breast Cancer Therapeutics, Global, Licensing Deals by Phase and Value, 2006-2013
  • Figure 19: Breast Cancer Therapeutics, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006-2013
  • Figure 20: Breast Cancer Therapeutics, Global, Licensing Deals by Region, 2006-2013
  • Figure 21: Breast Cancer Therapeutics, Global, Co-development Deals by Phase and Value, 2006-2013
  • Figure 22: Breast Cancer Therapeutics, Global, Co-development Deals, 2006-2013
  • Figure 23: GBI Research Market Forecasting Model
Back to Top